NHGRI is about to start Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study
Photo by Laura Margarita Cedeño Peralta
National Human Genome Research Institute (NHGRI) is conducting the clinical trial Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)/GENE-FORECAST SIT.
The objective of this study is to implement a sodium intervention investigation to assess the effect of increased dietary sodium intake on changes in blood pressure, vascular function, microbiome, whole blood epigenome, whole blood and urine transcriptome as outcome measures. It is hypothesized that exposure to increased dietary sodium will affect blood pressure, whole blood epigenome, whole blood and urine transcriptome, vascular function, microbiome and blood pressure.
It is planned to include 150 participants.
Actual study start date is January 27, 2021. The researchers expect to complete the study by July 3, 2023.
The population that can be enrolled into this study includes African American men and women who are former GENE-FORECAST participants between 21 and 65 years of age.
Among the criteria that do not allow participation, the following are indicated:
- Individuals who are pregnant or breast-feeding.
- Individuals with high blood pressure or a history of hypertension.
- Individuals with a history of myocardial infarction, stroke, heart failure, diabetes, chronic liver or kidney diseases.
- Individuals who are taking antihypertensive, antidepressants, antidiabetic and antibiotic medications.
- Individuals currently participating in another NIH protocol.
The location of the study is as follows (further details can be found here https://ichgcp.net/clinical-trials-registry/NCT04717336) Bethesda, United States.
